"Our plan is to finish the pre-IPO by the end of this year and move to IPO early next year," said the company's CEO Dr Chengbin Wu, although Wu is still keeping his options open in terms of where to list EpimAb. Competitors Merus and Affimed are Nasdaq-listed, while fellow Chinese firm RemeGen chose to IPO closer to home in Hong Kong for USD 592 million in November 2020. "The US is one of the markets we are considering in addition to Hong Kong," stated Wu.